6.
Mao Y, Wang W, Yang J, Zhou X, Lu Y, Gao J
. Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids. Protein Cell. 2023; 15(4):285-304.
PMC: 10984622.
DOI: 10.1093/procel/pwad038.
View
7.
Wang T, Tang Y, Pan W, Yan B, Hao Y, Zeng Y
. Patient-Derived Tumor Organoids Can Predict the Progression-Free Survival of Patients With Stage IV Colorectal Cancer After Surgery. Dis Colon Rectum. 2023; 66(5):733-743.
PMC: 10072204.
DOI: 10.1097/DCR.0000000000002511.
View
8.
Shen X, Zhang Y, Xu Z, Gao H, Feng W, Li W
. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response. Cell Death Dis. 2022; 13(4):303.
PMC: 8980070.
DOI: 10.1038/s41419-022-04773-1.
View
9.
Tan R, Zhang Z, Ding P, Liu Y, Liu H, Lu M
. A growth factor-reduced culture system for colorectal cancer organoids. Cancer Lett. 2024; 588:216737.
DOI: 10.1016/j.canlet.2024.216737.
View
10.
Janakiraman H, Zhu Y, Becker S, Wang C, Cross A, Curl E
. Modeling rectal cancer to advance neoadjuvant precision therapy. Int J Cancer. 2020; 147(5):1405-1418.
DOI: 10.1002/ijc.32876.
View
11.
Prigerson H, Bao Y, Shah M, Paulk M, LeBlanc T, Schneider B
. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncol. 2015; 1(6):778-84.
PMC: 4828728.
DOI: 10.1001/jamaoncol.2015.2378.
View
12.
Zhou C, Wu Y, Wang Z, Liu Y, Yu J, Wang W
. Standardization of organoid culture in cancer research. Cancer Med. 2023; 12(13):14375-14386.
PMC: 10358246.
DOI: 10.1002/cam4.5943.
View
13.
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin A, Kim S
. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483(7391):603-7.
PMC: 3320027.
DOI: 10.1038/nature11003.
View
14.
Usui T, Sakurai M, Umata K, Elbadawy M, Ohama T, Yamawaki H
. Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture. Int J Mol Sci. 2018; 19(4).
PMC: 5979580.
DOI: 10.3390/ijms19041098.
View
15.
Mertens S, Huismans M, Verissimo C, Ponsioen B, Overmeer R, Proost N
. Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer. Cell Rep. 2023; 42(4):112324.
DOI: 10.1016/j.celrep.2023.112324.
View
16.
Seymour M, Maughan T, Ledermann J, Topham C, James R, Gwyther S
. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet. 2007; 370(9582):143-152.
DOI: 10.1016/S0140-6736(07)61087-3.
View
17.
Gao S, Soares F, Wang S, Wong C, Chen H, Yang Z
. CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer. Oncogene. 2021; 40(48):6601-6613.
PMC: 8639446.
DOI: 10.1038/s41388-021-01882-7.
View
18.
Buczacki S, Popova S, Biggs E, Koukorava C, Buzzelli J, Vermeulen L
. Itraconazole targets cell cycle heterogeneity in colorectal cancer. J Exp Med. 2018; 215(7):1891-1912.
PMC: 6028508.
DOI: 10.1084/jem.20171385.
View
19.
Jensen L, Rogatto S, Lindebjerg J, Havelund B, Abildgaard C, Matos do Canto L
. Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study. J Exp Clin Cancer Res. 2023; 42(1):115.
PMC: 10161587.
DOI: 10.1186/s13046-023-02683-4.
View
20.
Michels B, Mosa M, Streibl B, Zhan T, Menche C, Abou-El-Ardat K
. Pooled In Vitro and In Vivo CRISPR-Cas9 Screening Identifies Tumor Suppressors in Human Colon Organoids. Cell Stem Cell. 2020; 26(5):782-792.e7.
DOI: 10.1016/j.stem.2020.04.003.
View